Estrogen replacement therapy in women with previously treated breast cancer. ACOG Committee Opinion: Committee on Gynecologic Practice Number 135-April 1994.
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016022:Case-Control Studies; D004273:DNA, Neoplasm / Q000032:analysis; D003692:Delayed-Action Preparations; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000235:genetics; D009644:Norgestrel / Q000009:adverse effects / Q000627:therapeutic use; D017698:Postmenopause; D012334:RNA, Neoplasm / Q000032:analysis; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use
D004273:DNA, Neoplasm; D003692:Delayed-Action Preparations; D004966:Estrogens, Conjugated (USP); D012334:RNA, Neoplasm; D013629:Tamoxifen; D009644:Norgestrel; D017258:Medroxyprogesterone Acetate